|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.015 AUD | -11.76% |
|
-11.76% | -25.00% |
| Apr. 10 | Syntara Reaches 50% Recruitment in Phase 2 Trial for Bone Marrow Cancer Treatment | MT |
| Feb. 29 | Syntara Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Pharmaxis Ltd reported earnings results for the full year ended June 30, 2023. For the full year, the company reported revenue was AUD 19.31 million compared to AUD 15.91 million a year ago. Net loss was AUD 11.36 million compared to AUD 1.94 million a year ago.
Basic loss per share from continuing operations was AUD 0.0002 compared to AUD 0.0004 a year ago. Diluted loss per share from continuing operations was AUD 0.0002 compared to AUD 0.0003 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -25.00% | 13.24M | |
| +26.47% | 661B | |
| +26.74% | 566B | |
| -6.33% | 352B | |
| +19.35% | 332B | |
| +4.23% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -4.04% | 145B |
SYNTARA LIMITED 
